Insider Transactions in Q4 2025 at Athira Pharma, Inc. (ATHA)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 31
2025
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,667
+14.54%
|
-
|
|
Dec 31
2025
|
Robert Renninger Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,236
+8.59%
|
-
|
|
Dec 31
2025
|
Mark James Litton President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,834
+19.97%
|
-
|
|
Dec 31
2025
|
Martin Javier San CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,667
+28.28%
|
-
|
|
Dec 31
2025
|
Mark Worthington General Counsel and CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,667
+19.8%
|
-
|
|
Dec 23
2025
|
Perceptive Advisors LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
1,319,026
+44.64%
|
$7,914,156
$6.35 P/Share
|
|
Nov 18
2025
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+5.29%
|
$2,000
$2.31 P/Share
|
|
Nov 18
2025
|
Robert Renninger Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+7.74%
|
$2,000
$2.31 P/Share
|